X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Survivin-targeted T cell therapy continues to show significant, durable anti-tumor activity and is well-tolerated in this hard-to-treat cancer patient population.
Lead Product(s): DPX-Survivac,Cyclophosphamide,Epacadostat
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
Details:
BriaCell's Phase I/IIa clinical study of Bria-IMT™, for breast cancer treatment, with Incyte’s immune checkpoint inhibitor, INCMGA00012, is ongoing and recruiting patients amidst COVID-19 pandemic.
Lead Product(s): SV-BR-1-GM,INCMGA00012,Epacadostat
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2020
Details:
The presentation will highlight clinical data and pathological findings from the Phase I/IIa studies of Bria-IMT™ alone or in combination with checkpoint inhibitors in advanced breast cancer patients.
Lead Product(s): SV-BR-1-GM,INCMGA00012,Epacadostat
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2020
Details:
First in-vivo T cell therapy to demonstrate clinical activity in hard-to-treat solid tumor.
Lead Product(s): DPX-Survivac,Cyclophosphamide,Epacadostat
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
